Skip to main content

Table 1 Characteristics of Ph + leukemia survivors by diagnosis

From: Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias

  CML (N = 44) Ph + ALL (N = 22)
N (%) N (%)
Clinical Characteristics
 Sex
  Male 21 (47.7) 12 (54.5)
  Female 23 (52.3) 10 (45.5)
 Race and ethnicity
  White non-Hispanic 11 (25.0) 7 (31.8)
  Black non-Hispanic 12 (27.3) 3 (13.6)
  Hispanic 5 (11.4) 8 (36.4)
  Asian 14 (31.8) 2 (9.1)
  Other/Not Stated 2 (4.5) 2 (9.1)
 Age at diagnosis, years 13 (3, 20)* 11 (3, 20)*
 Age at censoring, years 19 (6, 35)* 17.5 (6, 26)*
 Time under observation, years 6.3 (1.1, 15.8)* 5.7 (2.1, 11.8)*
Treatment Information
 Tyrosine kinase inhibitor
  Imatinib 35 (79.5) 14 (63.6)
  Dasatinib 26 (59.1) 16 (72.7)
  Nilotinib 7 (15.9) 0 (0.0)
  Ponatinib 2 (4.5) 0 (0.0)
  Bosutinib 1 (2.3) 0 (0.0)
  More than one TKI 21 (47.7) 8 (36.4)
 Duration of TKI treatment, yearsa 6.3 (0.9, 15.6)* 2.8 (0.6, 11.6)*
 Cranial radiation
  Yes 0 (0.0) 6 (27.3)
  No 44 (100.0) 16 (72.7)
 Clinical trial enrollment
  Enrolled 6 (13.6) 9 (40.9)
  Not enrolled 38 (86.4) 13 (59.1)
  1. * Median (minimum, maximum) for continuous variables
  2. aTKI treatment duration for Ph + ALL reflects 1 patient who completed all planned therapy in 0.6 years (hyper-CVAD + TKI) and 6 patients who continued single-agent TKI after upfront therapy